RxDoctor Payments Data

Mark Klafter, DO

Neurology · Orlando, FLNPI 1730161639

Payments from drug & device makers

$247,403in general payments, 2019–2025

Across 1,878 payments — averaging $131.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$95K
  • Acadia Pharmaceuticals Inc$80K
  • Acorda Therapeutics, Inc$32K
  • Teva Pharmaceuticals USA, Inc.$18K
  • Sanofi$2K
  • Amgen$2K
  • plus $19K from 54 others

What the payments were for

  • Consulting fees$5,6502%
  • Speaking & faculty fees$187,73576%
  • Travel & lodging$19,6428%
  • Food & beverage$34,24914%
  • Education$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)298$95,231
Acadia Pharmaceuticals Inc260$80,283
Acorda Therapeutics, Inc57$31,687
Teva Pharmaceuticals USA, Inc.103$17,985
Sanofi75$1,929
Amgen(2 entities)109$1,585
Biogen75$1,355
EMD Serono, Inc.67$1,095
AstraZeneca(2 entities)47$1,083
Novartis90$990
UCB, Inc.52$963
Jazz Pharmaceuticals Inc.34$802
Lilly USA, LLC51$792
Argenx US, Inc.42$746
Amneal Pharmaceuticals LLC35$689
Genentech USA, Inc.34$677
Harmony Biosciences LLC21$616
TG Therapeutics, Inc.28$581
Eisai Inc.21$517
CSL Behring21$475
Vanda Pharmaceuticals Inc.23$470
Pfizer28$449
MDD US Operations, LLC24$439
Sunovion Pharmaceuticals Inc.21$423
Bristol Myers Squibb38$405
Johnson & Johnson(2 entities)14$345
Alnylam Pharmaceuticals Inc.12$344
Neurocrine Biosciences, Inc.15$334
GE HealthCare16$312
Merz Pharmaceuticals, LLC9$244
ANI Pharmaceuticals, Inc.11$238
Grifols USA, LLC12$231
Kyowa Kirin, Inc.5$200
Lundbeck LLC9$199
Axsome Therapeutics, Inc.9$186
Adamas Pharmaceuticals, Inc.11$179
Takeda Pharmaceuticals U.S.A., Inc.6$173
Otsuka America Pharmaceutical, Inc.4$170
Abbott2$163
Supernus Pharmaceuticals, Inc.11$153
Biotronik Inc.1$139
Catalyst Pharmaceuticals, Inc.6$138
Banner Life Sciences, LLC6$115
Upsher-smith Laboratories LLC5$104
Mallinckrodt Enterprises LLC5$97
Corium, LLC5$86
Impel Pharmaceuticals LLC3$85
E.r. Squibb & Sons, L.L.C.4$84
Tanabe Pharma America, Inc.5$82
Merz North America, Inc.3$75
Biohaven Pharmaceuticals, Inc.4$70
Avion Pharmaceuticals4$70
Biohaven Pharmaceutical Holding Company Ltd.3$68
Cycle Pharmaceuticals Inc3$63
Avadel CNS Pharmaceuticals, LLC2$57
Boston Scientific3$47
Avanir Pharmaceuticals, Inc.3$43
C2n Diagnostics, LLC1$36
Revance Therapeutics, Inc.1$25
Arbor Pharmaceuticals, Inc.2$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$247,403 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$203,494
Medicare patients
390
Services billed
3,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate77$483,070
RytaryCarbidopa/Levodopa36$63,237
BotoxOnabotulinumtoxina21$40,422
Glatiramer Acetate13$18,042
NeuproRotigotine13$16,702
Carbidopa-LevodopaCarbidopa/Levodopa363$16,017
Rasagiline Mesylate53$10,096
Rivastigmine25$6,953
Pramipexole DihydrochloridePramipexole Di-Hcl191$6,513
XeominIncobotulinumtoxina16$5,269
Primidone61$2,580
Selegiline Hcl12$2,469
Donepezil Hcl99$2,155
AmantadineAmantadine Hcl44$2,131
Entacapone12$2,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$80,283$483,07077 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$689$64,08949 claims
AbbVieBotox$95,231$40,42221 claims
UCB, Inc.Neupro$963$16,70213 claims
Merz North America, Inc.Xeomin$75$5,26916 claims
PfizerDilantin$449$1,78012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →